Abstract
To study the cross-reactivity pattern of Shigella flexneri 2a O-antigen antibodies, sera from humans and monkeys challenged with S. flexneri 2a, and from humans and guinea pigs immunized with a recombinant vaccine expressing serotype 2a O-antigen, were tested against a panel of lipopolysaccharide extracted from heterologous S. flexneri. Sera from the two groups of humans, who were volunteers in either a clinical challenge or vaccination study, showed similar patterns: cross-reactivity was more often seen with IgA antibodies, and these were mostly cross-reactive with serotype 2b, which shares the type II antigen, and serotypes 1a, 5a, and Y, which share 4 or 3,4 group antigen, with 2a. The majority of sera from immunized guinea pigs showed both IgG and IgA cross-reactivity with 1a, 5a, and Y, but not 2b. The majority of sera from challenged monkeys showed cross-reactivity with almost all flexneri serotypes tested, with 1a, 2b, and Y being recognized most often, and the cross-reactive antibodies were more often IgG than IgA. These results show that either immunization or challenge with the 2a serotype induces cross-reactive antibodies which recognize similar subsets of heterologous serotypes, and suggest that it may be possible to design multivalent vaccines against S. flexneri.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1062-1068 |
| Number of pages | 7 |
| Journal | Vaccine |
| Volume | 14 |
| Issue number | 11 |
| DOIs | |
| State | Published - Aug 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- Antibodies
- Cross-reactivity
- LPS
- Shigella flexneri 2a
- Vaccine
ASJC Scopus subject areas
- Immunology
- Microbiology
- Virology
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
Cite this
Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. / Van De Verg, Lillian L.; Bendiuk, Natalie O.; Kotloff, Karen; Marsh, Michelle M.; Ruckert, Jennifer L.; Puryear, Jill L.; Taylor, David N.; Hartman, Antoinette B.; Oryshkewych, N. O.
In: Vaccine, Vol. 14, No. 11, 08.1996, p. 1062-1068.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection
AU - Van De Verg, Lillian L.
AU - Bendiuk, Natalie O.
AU - Kotloff, Karen
AU - Marsh, Michelle M.
AU - Ruckert, Jennifer L.
AU - Puryear, Jill L.
AU - Taylor, David N.
AU - Hartman, Antoinette B.
AU - Oryshkewych, N. O.
PY - 1996/8
Y1 - 1996/8
N2 - To study the cross-reactivity pattern of Shigella flexneri 2a O-antigen antibodies, sera from humans and monkeys challenged with S. flexneri 2a, and from humans and guinea pigs immunized with a recombinant vaccine expressing serotype 2a O-antigen, were tested against a panel of lipopolysaccharide extracted from heterologous S. flexneri. Sera from the two groups of humans, who were volunteers in either a clinical challenge or vaccination study, showed similar patterns: cross-reactivity was more often seen with IgA antibodies, and these were mostly cross-reactive with serotype 2b, which shares the type II antigen, and serotypes 1a, 5a, and Y, which share 4 or 3,4 group antigen, with 2a. The majority of sera from immunized guinea pigs showed both IgG and IgA cross-reactivity with 1a, 5a, and Y, but not 2b. The majority of sera from challenged monkeys showed cross-reactivity with almost all flexneri serotypes tested, with 1a, 2b, and Y being recognized most often, and the cross-reactive antibodies were more often IgG than IgA. These results show that either immunization or challenge with the 2a serotype induces cross-reactive antibodies which recognize similar subsets of heterologous serotypes, and suggest that it may be possible to design multivalent vaccines against S. flexneri.
AB - To study the cross-reactivity pattern of Shigella flexneri 2a O-antigen antibodies, sera from humans and monkeys challenged with S. flexneri 2a, and from humans and guinea pigs immunized with a recombinant vaccine expressing serotype 2a O-antigen, were tested against a panel of lipopolysaccharide extracted from heterologous S. flexneri. Sera from the two groups of humans, who were volunteers in either a clinical challenge or vaccination study, showed similar patterns: cross-reactivity was more often seen with IgA antibodies, and these were mostly cross-reactive with serotype 2b, which shares the type II antigen, and serotypes 1a, 5a, and Y, which share 4 or 3,4 group antigen, with 2a. The majority of sera from immunized guinea pigs showed both IgG and IgA cross-reactivity with 1a, 5a, and Y, but not 2b. The majority of sera from challenged monkeys showed cross-reactivity with almost all flexneri serotypes tested, with 1a, 2b, and Y being recognized most often, and the cross-reactive antibodies were more often IgG than IgA. These results show that either immunization or challenge with the 2a serotype induces cross-reactive antibodies which recognize similar subsets of heterologous serotypes, and suggest that it may be possible to design multivalent vaccines against S. flexneri.
KW - Antibodies
KW - Cross-reactivity
KW - LPS
KW - Shigella flexneri 2a
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=0030219969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030219969&partnerID=8YFLogxK
U2 - 10.1016/0264-410X(96)00006-0
DO - 10.1016/0264-410X(96)00006-0
M3 - Article
C2 - 8879103
AN - SCOPUS:0030219969
VL - 14
SP - 1062
EP - 1068
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 11
ER -